It has a new double-tap feature and brighter screen, but latest model has same battery life the watches have had since 2015: 18 hours
4 min
If you asked me, “Should I upgrade my Apple Watch to the Series 9 this year?” I’d probably say no.
It’s a fine watch. It’s just not much better than the Series 8, which you can get cheaper, even refurbished right from Apple.
I have been testing the $399-and-up Series 9 for nearly a week. Available on Sept. 22, it includes a few upgrades, including a one-handed, double-tap gesture and a brighter screen. Apple says one version of it—the aluminium case with Sport Loop band—is carbon neutral.
Many things, though, remain unchanged from last year’s, including the health sensors and design. I’m most grumpy about the battery life. Back in 2015, Apple promised 18 hours. Today, Apple promises…18 hours. Eight years and a dozen models later, we still need to charge these watches daily.
The Apple Watch is the bestselling smartwatch in the world, but battery life is where competitors such as Garmin still have an edge. It’s what holds the Apple Watch back from true all-day/all-night/all-weekend usefulness.
The improvements to the Series 9 are internal, enabling new features that are nice-to-haves. There are no game-changers.
Double tap: The new watch senses when you pinch your thumb and index finger twice, in quick succession. The gesture triggers an action that varies depending on what you’re doing. If you’re playing a song, you can double-tap to pause or skip. For incoming texts, it starts a reply with voice dictation. For calls, it picks up the phone. For timers, it dismisses the alert.
Double tap will come in an update rolling out next month. It’s useful for one-handed operation, while you’re holding on to a subway pole or cup of coffee. It also works while you’re wearing gloves.
A similar accessibility feature called AssistiveTouch is available on Series 4 models and newer. You can even double-pinch to dismiss notifications. In my tests, AssistiveTouch wasn’t always as responsive as double-tapping on the Series 9, but if you already have an Apple Watch, it’s worth enabling.
Offline Siri: Apple’s voice assistant can now process some queries faster and more accurately, because it doesn’t need to send the request to the server over Wi-Fi or cellular. You can set timers—even multiple timers in the WatchOS 10—almost instantaneously.
Brighter screen: The display goes up to 2,000 nits, up from 1,000 nits last year. If you don’t speak nits, that translates to a screen that’s easier to see outdoors on a sunny day. Its dimmest setting is also lower, way down to one nit. The Apple Watch adjusts screen brightness automatically based on ambient light, so the brighter screen isn’t noticeable in most settings.
Precision iPhone finding: I use my Apple Watch’s Find My iPhone ping basically every day, so I thought I’d like precision finding. When you’re within about 30 feet of the iPhone, you can see its distance and direction—similar to an AirTag. It’s nice for those who might be unable to hear the audible ping triggered by older models, but that never failed me. And this trick only works with an iPhone 15 model.
In its quest to make the smartwatch a jack-of-all-trades wearable with a high-resolution, multitouch screen, Apple has sacrificed battery life. The new S9 processor is 25% more power efficient than last year’s model. But over the years, the company has added more sensors, brighter screens and other energy-sucking elements.
During the watch’s recent unveiling, Deidre Caldbeck, the director of Apple Watch product marketing, highlighted the company priority: “This powerful custom silicon is what allows us to maintain all-day 18-hour battery life while adding new features and systemwide improvements.”
Garmin wearables, meanwhile, have lower-resolution displays that can last days. Some models have solar panels embedded in their watch faces, and can last weeks. It’s something I’m painfully reminded of every time I forget my Apple Watch charger on a weekend trip. Cue the gloating by my Garmin-wearing husband, who never brings his charger.
Apple often touts the watch’s health-tracking capabilities in marketing materials. For this to work, though, it has to be on your wrist—even at night, while you sleep. That’s tough when it needs to be charged once a day.
Charging wouldn’t be as problematic if the Apple Watch didn’t need its own proprietary puck to power up. (Garmin’s new Vivomove Trend is one of the first to work with standard Qi wireless charging.)
I’m not saying Apple Watches are useless without default multi day battery life. I wear mine so often that I have a squircle-shaped tan on my wrist. But a battery-life quantum leap is needed.
That could be coming next year. The Apple Watch was announced 10 years ago next fall, and that anniversary could mean a big redesign. According to a Bloomberg report, a new band system could make room in the watch’s case for more sensors—or, I hope, a bigger battery—and a switch to a more energy-efficient microLED display could lead to power gains.
If you want the longest battery life right now, there’s the $799 Apple Watch Ultra. It lasts a day and a half by default. But even the new, modestly upgraded model is a bulky chunkster, especially on smaller wrists. Anyone else looking for a big Apple Watch change should wait until 2024.
Meanwhile, you can temporarily double the battery life by taking away power-draining features.
• Enable low-power mode: You can quickly enable low-power mode for set periods. Press the side button to open the Control Center, then tap on the battery percentage and scroll down.
Just beware: It does disable some of the lifesaving heart-rate notifications and the power-hungry always-on display. When double tap is available, low-power mode will also disable that gesture.
• Reduce workout sensor readings: Go to Settings > Workout, then tap Fewer GPS and Heart Rate Readings to enable. When in low-power mode, the watch won’t capture GPS or heart-rate data as frequently during outdoor workouts, further extending battery life.
You can also disable some functions. I managed to squeeze 48 hours out of the Series 9 by turning off the most battery-intensive ones, but it’s a trade-off:
• Double tap: When the feature rolls out to Series 9 models next month, you can turn it off. Go to Settings > Gestures > Double Tap to disable.
• Always-on display: Go to Settings > Display & Brightness. Tap Always On to disable.
• Background app refresh: Go to Settings > General. Scroll down to Background App Refresh to disable entirely or turn off for certain apps.
• Reduce display brightness: In Settings > Display & Brightness, you can adjust the default setting.
Copyright 2020, Dow Jones & Company, Inc. All Rights Reserved Worldwide. LEARN MORE
Following the successful launch of its Palais Collection, MAISON de SABRÉ has unveiled a new modular handbag system offering more than 720 styling combinations.
Automobili Lamborghini and Babolat have expanded their collaboration with five new colourways for the ultra-exclusive BL.001 racket, limited to just 50 pieces worldwide.
As millions flock to GLP-1s, doctors warn the drugs can cause rapid and significant muscle loss.
5 min
Chanel Robinson achieved exactly what the gold rush of blockbuster weight-loss drugs promised: She lost nearly 100 pounds, lowered her cholesterol to normal levels and reined in her polycystic ovary syndrome.
Yet, nearly three years into her journey on Mounjaro, the 30-year-old from Atlanta, Ga., is discovering the hidden costs of the slimmed-down life.
Robinson experiences muscle fatigue daily, feeling physically weak, frail and often cold. Robinson said she experiences bursts of sluggishness sporadically during the day, and has trouble with basic tasks like opening a jar. “It shouldn’t be this difficult,” she said.
GLP-1 drugs like Ozempic, Mounjaro and Zepbound have been a success for public health and the pharmaceutical companies that make them. Obesity rates are falling, the volume of food consumed in America is declining and retailers report a slump in sales of plus-size apparel. It has improved health and happiness for millions of people.
But for at least some of the 13 million Americans taking them, losing muscle along with fat is an unexpected downside that isn’t broadly discussed or immediately apparent.
The drugs can cause rapid and significant loss of lean muscle mass, up to 10%, comparable to a decade or more of aging, according to an analysis published by the American Diabetes Association.
The loss of lean tissue is similar to weight loss from dieting, but the magnitude over a short period can lead to frailty, instability and lack of coordination, doctors and researchers say. Another concern is that losing muscle could slow down patients’ metabolism, leading to weight regain.
“We are curing obesity by encouraging frailty,” said Daniel Green, principal research fellow at the University of Western Australia, who contributed to the analysis. Many taking weight-loss medications initially lose fat and feel great, but quickly start to feel weak and lethargic, he said.
Green’s research showed that the rate of muscle loss could be slowed significantly by regular strength workouts. “It should say ‘must be taken with resistance training’ on the box,” he said.
Drugmakers say weight-loss drugs should be taken only on the advice of a physician and as part of a long-term plan that includes diet and exercise.
A spokesperson for Eli Lilly, maker of Zepbound, said Food and Drug Administration guidelines say it should be used “with increased physical activity.” The spokesperson added: “Sustainable weight loss is about more than a number on a scale.”
Both Eli Lilly and Novo Nordisk said clinical trials showed users did lose some lean muscle tissue, though at far lower rates than fat. Liz Skrbkova, a spokeswoman for Novo Nordisk, said that trials for its drug Wegovy showed changes in muscle mass didn’t “significantly differ” from patients who took a placebo. Eli Lilly said users lost three times more fat weight than lean tissue.
Rayna Kingston, 30, from Denver, said her injections of Zepbound left her feeling so tired the following day that she struggled to complete anything other than basic tasks. She said she shifted her dose to a Sunday because Mondays were her least busy day. Her partner would bring her meals in bed because she felt so weak.
She stopped exercising, and said her doctor didn’t give her any guidance on strength training or muscle maintenance. “I was relying on Reddit forums to understand what was happening to my body,” she said. She got so frustrated with the fatigue she came off the medication just under two months later.
Experts say that losing muscle at such a rate can be especially dangerous for those over 50 or with osteoporosis or limited mobility as it could lead to an increased risk of injury. “Loss of muscle mass is detrimental to moving around and quality of life, but it is also not safe,” said Katsu Funai, associate professor at the University of Utah.
Elderly Americans are set to be able to get GLP-1s from Medicare from July.
There is also pushback from doctors and regulators against using weight-loss drugs as a “quick fix” to lose a bit of weight.
People who take GLP-1s regain weight four times faster than those who lose weight through lifestyle interventions, and weight regained is often mostly fat, according to a recent analysis published in the British Medical Journal. There currently are few, if any, guidelines or studies on de-prescribing the drugs, researchers say.
The nurse practitioner who prescribed Robinson the medication didn’t warn her that resistance training is essential to maintaining muscle mass, Robinson said. She said she regrets not exercising and now does Pilates once a week.
In the haste to disrupt the obesity epidemic, weight loss has been treated as the singular, undisputed metric of success, which experts say is problematic.
“People worship body weight as an outcome measure because it’s simple, quick and inexpensive,” said Green. “But what matters is fat and muscle mass, which is more expensive to measure as it requires an MRI.”
Grace Parkin, 34, a property manager from Sheffield, England, has lost 125 pounds after she started taking Mounjaro in 2024. “I don’t care about my muscle mass as long as I’m a healthy weight,” she said.
The doctor who prescribed the drug didn’t tell her to exercise, though the pharmacy that sold the medication gave her information on exercise and protein intake, she said.
She didn’t exercise and said she soon felt side effects: a “deathly cold, from the inside” likely because of the drug. Still, she vowed to keep going, saying the weight loss was worth it.
In response to some of the side effects, drug companies are hoping to develop weight-loss treatments aimed at preserving or even building lean muscle mass.
German drugmaker Boehringer Ingelheim recently said it had promising results from one such drug. Eli Lilly last September halted a trial of a similar drug.
While weight-loss medications are designed as lifelong treatments for chronic diseases, namely obesity and Type 2 diabetes, they are increasingly marketed as lifestyle fixes.
Tennis superstar Serena Williams, who used GLP-1s to slim down after having children, was featured in this year’s Super Bowl commercial promoting telehealth company Ro’s weight-loss medication.
Serena Williams poses for an ad campaign for a weight-loss drug. Ro/Handout/Reuters
Women may be particularly vulnerable to the drugs’s side effects, which can also include nausea, diarrhea, migraines and rarer cases of pancreatitis.
A study last year from a university hospital in Turin, Italy, showed that women are more prone to adverse reactions to weight-loss drugs than men, including muscle loss.
Green, the researcher, said the issue is of particular concern to those taking GLP-1s recreationally and who don’t have much muscle mass to begin with. Others say a lack of oversight is compounding the issue.
“Patients are self-reporting, and telehealth companies don’t have the patient in front of them to conduct a proper medical assessment,” said Rupal Mathur, an internist in Houston whose practice specializes in weight loss.
She said medical spas are prescribing off-label drugs that don’t meet the criteria set out by the FDA that justify a prescription.
The number of people taking weight-loss drugs who are not living with obesity or Type 2 diabetes is difficult to track since it is unregulated.
However, an analysis by the FDA from 2023 found that more than half of new Ozempic and Mounjaro users didn’t have Type 2 diabetes.
Scientists are calling for more clinical trials to pin down the full effects of weight-loss drugs on muscle loss in different demographics.
“The only studies that have been done have looked at people living with obesity or Type 2 diabetes,” said Green. “That makes it all the more concerning for those using weight-loss drugs in an ad hoc or unregistered way.”
